Obviously lots of real world data at #EULAR2023 on JAKi safety (cardiovascular & cancer, see ORAL Surveillance). Real problem: many still have shorter follow-up periods. Cancer in particular takes time. It’s great to see data now, but: *longer follow-up needed* +++ @RheumNow https://t.co/YH4fZgNQjY